The approval question requires the name of an actual product. GEREF was a historical branded sermorelin medicine. That history does not confer FDA approval on a preparation currently made by a compounding pharmacy and sold through an online program.
The FDA states that compounded drugs are not FDA-approved. This means the agency does not review those individual preparations for safety, effectiveness, and quality before marketing in the way it reviews an approved drug. A review site should make that distinction visible even when discussing its featured advertiser.
The FDA states that compounded drugs are not FDA-approved. This means the agency does not review those individual preparations for safety, effectiveness, and quality before marketing in the way it reviews an approved drug. A review site should make that distinction visible even when discussing its featured advertiser.
What the GEREF record says
In a 2013 Federal Register determination, FDA addressed specified GEREF injection products and concluded that they had not been withdrawn from sale for reasons of safety or effectiveness. The notice concerns named historical products and a particular regulatory question.
It should not be translated into 'every sermorelin prescription is approved' or 'sermorelin was banned as unsafe.' Both statements erase the scope of the determination. Equally, the notice does not prove that a current product will improve an adult's sleep, recovery, or appearance.
Why an ingredient name is not enough
A prescription includes more than an active ingredient: formulation, strength, route, excipients, preparation method, packaging, and handling all matter. A pharmacy's compounded vial is not automatically the historical branded product. An oral or nasal product introduces further differences.
Read our format comparison if a provider switches between injection, tablet, and spray claims. Evidence about one route should not be used as proof that all routes produce the same exposure or result.
Licensed, registered, and approved
A professional license concerns a person or business operating under relevant requirements. Facility registration concerns a facility. Drug approval concerns a specific product and use under the applicable approval. These words should not be used interchangeably on a treatment page.
The FDA's compounding questions and answers explains the role of compounding and its limits. Our pharmacy guide turns that distinction into practical questions about who dispenses your medicine and which label applies.
What a provider should explain
Ask why the proposed preparation is appropriate for your situation, which pharmacy will supply it, and what evidence supports the intended use. The prescriber and pharmacist should be able to discuss uncertainties without relying on an approval badge or a general statement that the ingredient has a long history.
Regulatory status and clinical suitability remain separate questions. A medicine being available through a prescription pathway does not establish that it is necessary for normal aging. The Endocrine Society's aging statement distinguishes normal aging from endocrine disease and does not endorse GH-related treatment as a proven anti-aging intervention.
How we apply this in reviews
Our CoreAge Rx review uses the same standard as every other provider review: an advertised compounded offer is described as compounded, with no implied FDA approval or guaranteed result. Sponsorship affects placement, not the regulatory status of the product. Bring any confusing wording to your clinician before making a purchase decision.
The source notes
Sources & further reading
Provider pages document advertised offers, not independently proven outcomes. Historical references may concern different products or uses. Sources were checked for this edition on September 21, 2026; offers can change.